NCT02973204View on ClinicalTrials.gov

Circulating Tumor Cells and Tumor DNA in HCC and NET

CompletedOBSERVATIONAL
Enrollment

167

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 8, 2020

Study Completion Date

January 8, 2020

Conditions
Carcinoma, HepatocellularNeuroendocrine Tumors
Interventions
DRUG

Sorafenib

PROCEDURE

Radiofrequency ablation (RFA) or surgery

Intended curative surgery or RFA

DRUG

Everolimus

DRUG

Lanreotide

Or other somatostatin analogues (SSTA), eg. Sandostatin

Trial Locations (1)

8000

Department of Hepatology and Gastroenterology, Aarhus

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

lead

University of Aarhus

OTHER

NCT02973204 - Circulating Tumor Cells and Tumor DNA in HCC and NET | Biotech Hunter | Biotech Hunter